Inhibikase Therapeutics (IKT) Misses Q3 EPS by 13c

Inhibikase Therapeutics (NASDAQ: IKT) reported Q3 EPS of ($0.13).

For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.

You May Also Be Interested In

• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform